Approval · Notice of Compliance 11445 · 2010
RASILEZ: Notice of Compliance 11445
Issued May 25, 2010
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 11445
- Date
- May 25, 2010
- Company
- Novartis Pharmaceuticals Canada Inc.Montreal, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Update package labels to approved indication
- Therapeutic class
- Renin inhibitor
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| RASILEZ | Not yet assigned | — |
Medicinal ingredients
- ALISKIREN FUMARATE 150 MG per TAB
- ALISKIREN FUMARATE 300 MG per TAB